Author(s) :

Tevez Leung.

Volume/Issue :

Abstract :

Metal Organic Frameworks (MOFs) are a novel class of materials that have great promise in the biomedical field owing to their preclinical success. Despite 15 years of demonstrated success in preclinical trials, only two hafnium-based MOFs (RiMO-301 and RiMO-401) have entered clinical testing. This paper aims to examine this bench-to-bedside gap in MOFs with the question: What are the key factors that contribute to the success of MOFs in preclinical studies but hinder their translation into the clinic? Through a comparative analysis of 19 MOFs, including well studied MOF groups such as Zeolitic imidazolate framework MOFs (ZIF) and Material Institute of Lavoisier MOFs (MIL), this literature review will identify the advantages over conventional nanocarriers established from preclinical testing, and the multifaceted barriers hindering clinical translation. Furthermore, it discusses systematic strategic approaches to guide MOF research into clinical transition. By synthesizing these insights, the paper aims to provide a roadmap for overcoming transitional bottlenecks.